Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical Trials Insight: 700020515

Trial Profile

Clinical Trials Insight: 700020515

Phase of Trial: Phase III

Latest Information Update: 09 Mar 2010

At a glance

  • Drugs Sitimagene ceradenovec; Temozolomide
  • Indications Glioma
  • Focus Registrational; Therapeutic Use
  • Sponsors Ark Therapeutics
  • Most Recent Events

    • 09 Mar 2010 Ark Therapeutics has withdrawn its MAA, according to a company media release. The EMEA's Scientific Advisory Group on Oncology re-examined the filing and concluded that this trial did not provide sufficient evidence of a clincial benefit.
    • 21 Dec 2009 The EMEA's CHMP adopted a negative opinion regarding the MAA, according to an Ark media release. The Committee's negative opinion was based on possible differences between groups in treatment delays, which could have affected the primary endpoint.
    • 14 Oct 2009 Results will be presented at the American Society of Neuro-Oncology Conference in New Orleans on 22 October 2009, according to an Ark Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top